Cancer Registry Software Market to be propelled at a 10.4% CAGR until 2034, Reaching a Valuation of US$ 236.0 million | Future Market Insights, Inc.
Summary
NEWARK, Del, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Driven by international collaborative research activities, the worldwide cancer registry software market is expected to reach a worth of US$ 87.4 million in 2024. Pharmaceutical companies, regulatory agencies, and healthcare payers increasingly rely on real-world evidence to inform clinical decision-making, drug development, and reimbursement policies. Cancer registry software facilitates the generation of RWE by aggregating and analyzing real-world patient data, supporting comparative effectiveness research, post-market surveillance, and pharmacovigilance activities. AI-driven algorithms can identify patterns, predict outcomes, and personalize treatment recommendations based on individual patient characteristics and disease profiles, driving advancements in precision oncology. This helps ingest, analyze, and integrate cancer surveillance systems, enabling continuous monitoring of patient symptoms in real-time,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).